Rosetta Biosoftware 'Business as Usual' Despite Merck's Restructuring | GenomeWeb
NEW YORK (GenomeWeb News) – Merck’s Rosetta Biosoftware unit will be unaffected by the pharma giant’s recently announced restructuring, a Rosetta spokesperson told GenomeWeb Daily News today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.